What are the side effects of Thorazine (chlorpromazine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Thorazine Side Effects

Thorazine (chlorpromazine) causes a wide range of side effects, with the most concerning being extrapyramidal symptoms, sedation, cardiovascular effects, and rare but serious complications like neuroleptic malignant syndrome and tardive dyskinesia.

Major Categories of Side Effects

Neurological Side Effects

Extrapyramidal symptoms (EPS) are among the most common and problematic effects, particularly because chlorpromazine is a low-potency phenothiazine with significant anticholinergic properties 1.

Acute Extrapyramidal Effects:

  • Dystonia: Sudden spastic muscle contractions affecting neck, eyes (oculogyric crisis), or torso. Risk factors include young age, male gender. Can be life-threatening with laryngospasm 1, 2. Responds to anticholinergic or antihistaminic medications 1.
  • Parkinsonism: Bradykinesia, tremors, rigidity mimicking Parkinson's disease 1
  • Akathisia: Severe restlessness with pacing and agitation, often misinterpreted as psychotic agitation and leading to medication noncompliance 1

Tardive Dyskinesia:

This potentially irreversible syndrome involves rhythmical involuntary movements of tongue, face, mouth, or jaw (tongue protrusion, cheek puffing, chewing movements), sometimes with extremity involvement 3. There is no known effective treatment for tardive dyskinesia; antiparkinsonian agents do not alleviate symptoms 1. The syndrome can develop after long-term therapy or even brief treatment at low doses, appearing in all age groups but most prevalent in elderly patients, especially women 3.

Neuroleptic Malignant Syndrome (NMS):

A potentially fatal syndrome characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse/blood pressure, tachycardia, diaphoresis, cardiac dysrhythmias) 3. Management requires immediate discontinuation of chlorpromazine, intensive symptomatic treatment, and medical monitoring 3. Mortality has decreased from 76% in the 1960s to <10-15% currently 4.

Seizures:

Chlorpromazine lowers the seizure threshold in a dose-dependent manner 4, 1. While seizures are rare (<1%) at therapeutic doses, the risk increases with higher dosages 4.

Cardiovascular Side Effects

  • Orthostatic hypotension: Common due to alpha-adrenergic blockade 1
  • QTc prolongation: Can lead to dysrhythmias including torsades de pointes 5, 6. Risk increases with concomitant use of other QT-prolonging medications 6
  • Tachycardia and cardiac dysrhythmias 3
  • Sudden death: Rare reports, sometimes due to cardiac arrest or asphyxia from cough reflex failure 3

Anticholinergic Effects

As a low-potency phenothiazine, chlorpromazine has pronounced anticholinergic properties 1:

  • Sedation and drowsiness
  • Dry mouth
  • Nasal congestion
  • Constipation and adynamic ileus
  • Urinary retention
  • Blurred vision (miosis and mydriasis)
  • Cognitive blunting, apathy, and memory deficits 1

Metabolic and Endocrine Effects

  • Weight gain 1
  • Hyperprolactinemia leading to:
    • Lactation and breast engorgement 3
    • Amenorrhea and gynecomastia 3
    • Sexual dysfunction and ejaculatory disorders/impotence 3
  • Hyperglycemia, hypoglycemia, and glycosuria 3

Ocular Changes

With prolonged use (typically ≥2 years at doses ≥300 mg/day), patients may develop 3, 7:

  • Fine particulate deposits in lens and cornea
  • Star-shaped opacities in anterior lens
  • Epithelial keratopathy
  • Pigmentary retinopathy
  • Visual impairment in severe cases

The most prevalent ocular side effect is anterior lens capsule dusting, followed by corneal stromal pigment dusting 7. These changes may regress after drug withdrawal 3.

Dermatologic Effects

  • Photosensitivity: Avoid undue sun exposure 3
  • Skin pigmentation: Rare, slate-gray to violet discoloration in exposed areas, primarily in females on high doses (500-1500 mg/daily) for ≥3 years 3
  • Allergic reactions ranging from mild urticaria to severe exfoliative dermatitis and toxic epidermal necrolysis 3
  • Contact dermatitis in nursing personnel (use rubber gloves when administering) 3

Hematologic Effects

  • Anemia: May result from increased erythrocyte clearance due to phosphatidylserine exposure 8
  • Bone marrow depression (rare) 3

Hepatic Effects

  • Elevated liver enzyme levels
  • Cholestatic jaundice (specific to phenothiazines) 1

Other Serious Effects

  • Falls: Due to somnolence, postural hypotension, and motor/sensory instability, particularly concerning in elderly patients 3
  • Peripheral edema 3
  • Systemic lupus erythematosus-like syndrome 3
  • Priapism 3
  • Hyperpyrexia 3

Dose-Related Considerations

Higher doses (>800 mg/day) significantly increase the risk of extrapyramidal symptoms compared to lower doses (≤400 mg/day) 9. In overdose situations, CNS depression is the most common effect, with intubation associated with reported doses ≥2000 mg 10. The median dose requiring intubation in single-agent overdoses was 2500 mg 10.

Special Populations

Children and Adolescents

May be at higher risk for extrapyramidal side effects than adults 1. They may also have difficulty communicating concerns about side effects due to developmental issues 1.

Pregnancy

Neonates exposed during third trimester are at risk for extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorders) 3. Prolonged jaundice, extrapyramidal signs, and hyperreflexia/hyporeflexia have been reported in newborns 3.

Clinical Monitoring Recommendations

Before initiating chlorpromazine 11:

  • Baseline ECG (assess QTc interval)
  • Complete blood count
  • Liver function tests
  • Metabolic panel (glucose, lipids)
  • Blood pressure and BMI

During treatment 11:

  • Weekly monitoring for first 6 weeks (BMI, blood pressure)
  • Repeat metabolic parameters at 3 months, then annually
  • Periodic ocular examinations for patients on moderate-to-high doses long-term 3
  • Monitor for early signs of tardive dyskinesia (fine vermicular tongue movements) 3

Key Clinical Pitfalls

  1. Misinterpreting akathisia as psychotic agitation, leading to dose increases rather than decreases 1
  2. Antiemetic effect masking signs of toxicity from other drugs or conditions like intestinal obstruction 3
  3. Combining with other QT-prolonging medications without ECG monitoring 6
  4. Abrupt withdrawal after high-dose therapy can cause gastritis, nausea, vomiting, dizziness, and tremulousness 3
  5. Using in patients with Parkinson's disease or dementia with Lewy bodies due to high risk of extrapyramidal symptoms 5

References

Research

Upper airway compromise in acute chlorpromazine ingestion.

The American journal of emergency medicine, 1996

Research

Chlorpromazine dose for people with schizophrenia.

The Cochrane database of systematic reviews, 2017

Research

Chlorpromazine overdose: a case series.

Clinical toxicology (Philadelphia, Pa.), 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.